Clinical Trial

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and refractory/relapsed neuroblastoma in Sun Yat-sen University Cancer Center.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-22; most recent amendment 2025-06-13.
Trial Details
NCT Number NCT06013618
Lead Sponsor Sun Yat-Sen University Cancer Center
Collaborators: Hainan General Hospital
Conditions Neuroblastoma
Enrollment 120 participants
Start Date 2023-06-19
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-17